Brokerages predict that Intec Pharma Ltd (NASDAQ:NTEC) will post ($0.19) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Intec Pharma’s earnings. Intec Pharma posted earnings of ($0.32) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 40.6%. The company is scheduled to issue its next quarterly earnings report on Friday, April 6th.
According to Zacks, analysts expect that Intec Pharma will report full-year earnings of ($1.35) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will post earnings of ($0.89) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Intec Pharma.
Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings data on Wednesday, November 15th. The biotechnology company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.06).
A number of institutional investors have recently bought and sold shares of NTEC. Caxton Corp purchased a new stake in Intec Pharma during the 3rd quarter valued at about $681,000. Sectoral Asset Management Inc purchased a new stake in Intec Pharma during the 3rd quarter valued at about $3,177,000. Pura Vida Investments LLC purchased a new stake in shares of Intec Pharma in the third quarter worth about $895,000. Renaissance Technologies LLC boosted its stake in shares of Intec Pharma by 66.0% in the fourth quarter. Renaissance Technologies LLC now owns 133,500 shares of the biotechnology company’s stock worth $688,000 after buying an additional 53,100 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Intec Pharma by 59.2% in the fourth quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock worth $593,000 after buying an additional 42,867 shares during the last quarter. Institutional investors and hedge funds own 40.16% of the company’s stock.
Intec Pharma (NASDAQ NTEC) traded down $0.05 during midday trading on Tuesday, hitting $5.70. The stock had a trading volume of 41,602 shares, compared to its average volume of 93,704. Intec Pharma has a 1 year low of $4.20 and a 1 year high of $9.80.
TRADEMARK VIOLATION WARNING: “-$0.19 EPS Expected for Intec Pharma Ltd (NTEC) This Quarter” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.com-unik.info/2018/02/18/0-19-eps-expected-for-intec-pharma-ltd-ntec-this-quarter.html.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.